Skip to content

Study · Other design · n = 38 · 2015

4 results

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M

Clinical pharmacokinetics1 Mar 2015Cited by 4 (Europe PMC)

PMID25358450 (opens in a new tab)DOI10.1007/s40262-014-0202-x (opens in a new tab)PepBankPUB-25358450
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanOther designPharmacokinetics

    In HIV-infected patients and healthy subjects, population pharmacokinetic analysis estimated plasma clearance of tesamorelin and its interindividual variability.

    In plain wordsIn people with HIV and healthy people, the body cleared tesamorelin from blood at a rate estimated by a computer model.

    Peptide
    Tesamorelin
    Outcome
    Not applicablePlasma clearance of tesamorelin
    Study

    n = 38

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 or 2 mg daily · subcutaneous · 14 consecutive daysAs given in this study (human).

    Measurements

    Plasma clearance
    1060 L/h
    tesamorelin
    Interindividual variability (CV)
    33.6%
    clearance

    Source sentences

    Summary
    Plasma clearance and its interindividual variability [% coefficient of variation (CV)] was estimated to be 1,060 L/h (33.6 %).
    1 context sentence
    Summary · context
    A total of 38 HIV-infected patients and healthy subjects receiving subcutaneous tesamorelin doses of 1 or 2 mg administered daily during 14 consecutive days were included in the analysis.
  2. 02HumanOther designPharmacokinetics

    In HIV-infected patients and healthy subjects, population pharmacokinetic analysis estimated the volume of distribution of tesamorelin.

    In plain wordsIn people with HIV and healthy people, a computer model estimated how widely tesamorelin spreads in the body.

    Peptide
    Tesamorelin
    Outcome
    Not applicableVolume of distribution of tesamorelin
    Study

    n = 38

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 or 2 mg daily · subcutaneous · 14 consecutive daysAs given in this study (human).

    Measurements

    Volume of distribution
    200 L
    Interindividual variability (CV)
    17.7%
    volume of distribution

    Source sentences

    Summary
    Volume of distribution was calculated to be 200 L (17.7 %).
    1 context sentence
    Summary · context
    A total of 38 HIV-infected patients and healthy subjects receiving subcutaneous tesamorelin doses of 1 or 2 mg administered daily during 14 consecutive days were included in the analysis.
  3. 03HumanOther designPharmacokinetics

    In HIV-infected patients and healthy subjects, age, body size measures, race and health status were not related to tesamorelin pharmacokinetic parameters.

    In plain wordsIn people with HIV and healthy people, age, body size, race and health status did not change how the body handled tesamorelin.

    Peptide
    Tesamorelin
    Outcome
    No significant changeEffect of age, body size, race and health status on pharmacokinetics
    Study

    n = 38

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 or 2 mg daily · subcutaneous · 14 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    Age, body size measures, race and health status were not related to tesamorelin pharmacokinetic parameters within the range of covariates studied.
    1 context sentence
    Summary · context
    A total of 38 HIV-infected patients and healthy subjects receiving subcutaneous tesamorelin doses of 1 or 2 mg administered daily during 14 consecutive days were included in the analysis.
  4. 04HumanOther designPharmacokinetics

    In HIV-infected patients and healthy subjects, the fraction of tesamorelin absorbed by a first-order process was higher on day 14 than on day 1.

    In plain wordsIn people with HIV and healthy people, a larger share of tesamorelin was absorbed by the first-order process on day 14 than on day 1.

    Peptide
    Tesamorelin
    Outcome
    IncreaseFraction absorbed by first-order process, day 14 versus day 1
    Study

    n = 38

    Comparator
    Day 1
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1 or 2 mg daily · subcutaneous · 14 consecutive daysAs given in this study (human).

    Measurements

    Increase in fraction absorbed (first-order)
    13.1%
    day 14 vs day 1

    Source sentences

    Summary
    The fraction of tesamorelin absorbed by a first-order process is 13.1 % higher on day 14 compared with day 1.
    1 context sentence
    Summary · context
    A total of 38 HIV-infected patients and healthy subjects receiving subcutaneous tesamorelin doses of 1 or 2 mg administered daily during 14 consecutive days were included in the analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.